Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
Authors:
Open Access
- 1 December 2014
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 9, 93-102
Abstract
Objective: The aim of this study was to analyze the distribution of malignancies in patients after heart transplantation (HTX) and to evaluate the risk factors including immunosuppressive therapy with regard to the development of malignancies and survival. Special emphasis was placed on the effects of a mammalian target of rapamycin (mTOR) containing immunosuppressive regimen. Methods: A total of 381 patients (age ≥18 years) receiving HTX were included in the present analysis. All patients were followed-up at the University of Heidelberg Heart Center, Heidelberg, Germany. Data were retrieved from the Heidelberg Registry for Heart Transplantation being collected between 1989 and 2014. According to center standard, all patients received induction therapy with anti-thymocyte globulin guided by T-cell monitoring since 1994. The initial immunosuppressive regimen consisting of cyclosporine A (CsA) and azathioprine (AZA) was replaced by CsA and mycophenolate mofetil (MMF) in 2001 and by tacrolimus (TAC) and MMF in 2006. Additionally, mTOR inhibitors (everolimus/sirolimus) were applied since 2003. Results: Mean recipient age at HTX was 51.2±10.5 years and the mean follow-up period after HTX was 9.7±5.9 years. During follow-up, 130 patients developed a neoplasm (34.1% of total). Subgroup analysis revealed 58 patients with cutaneous malignancy only (15.2%), 56 patients with noncutaneous malignancy only (14.7%), and 16 patients with both cutaneous and noncutaneous malignancy (4.2%). Statistically significant risk factors associated with an increased risk of malignancy after HTX were older age (P1 treated rejection episode (TRE) in the first year after HTX (P=0.0091). Administration of CsA (P=0.0195), AZA (P=0.0008), or steroids (P=0.0018) for >1 year after HTX was associated with increased development of malignancy, whereas administration of MMF (PPP=0.0065) and noncutaneous malignancy mortality (P=0.0011) was significantly lower in patients receiving an mTOR inhibitor containing therapy after the development of a malignancy. Conclusion: This study highlights the complexity of risk factors including immunosuppression with regard to the development of malignancies after HTX. mTOR-inhibitor-based immunosuppression is associated with a better outcome after HTX, particularly in cases with noncutaneous malignancy.Keywords
This publication has 31 references indexed in Scilit:
- Fighting Malignancy in Organ Transplant RecipientsTransplantation Proceedings, 2009
- Metabolic syndrome and risk of cancer mortality in menEuropean Journal of Cancer, 2009
- Tacrolimus Versus Cyclosporine Microemulsion for Heart Transplant Recipients: A Meta-analysisThe Journal of Heart and Lung Transplantation, 2009
- The Impact of mTOR Inhibitors on the Development of MalignancyTransplantation Proceedings, 2008
- Malignancy After Heart Transplantation: Incidence, Prognosis and Risk FactorsAmerican Journal of Transplantation, 2008
- Is There a Role for Proliferation Signal/mTOR Inhibitors in the Prevention and Treatment of De Novo Malignancies After Heart Transplantation? Lessons Learned From Renal Transplantation and OncologyThe Journal of Heart and Lung Transplantation, 2007
- Mycophenolate Mofetil and Risk of Developing Malignancy After Orthotopic Heart Transplantation: Analysis of the Transplant Registry of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2006
- Taking Heart — Cardiac Transplantation Past, Present, and FutureNew England Journal of Medicine, 2006
- Effectivity of a T-Cell-Adapted Induction Therapy With Anti-Thymocyte Globulin (Sangstat)The Journal of Heart and Lung Transplantation, 2005
- Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trialsThe Lancet, 2005